PharmacoEconomics

1997 - 2025

Current editor(s): Timothy Wrightson and Christopher I. Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 35, issue 12, 2017

Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature pp. 1195-1209

Hamzeh Albaba, Charles Lim and Natasha B. Leighl

Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1211-1221

Nasuh C. Büyükkaramikli, Hedwig M. Blommestein, Rob Riemsma, Nigel Armstrong, Fiona. J. Clay, Janine Ross, Gill Worthy, Johan Severens, Jos Kleijnen and Maiwenn J. Al

Treatments for Metastatic Prostate Cancer (mPC): A Review of Costing Evidence pp. 1223-1236

Jan Norum and Carsten Nieder

Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice pp. 1237-1255

Rachel A. Elliott, Lukasz Tanajewski, Georgios Gkountouras, Anthony J. Avery, Nick Barber, Rajnikant Mehta, Matthew J. Boyd, Asam Latif, Antony Chuter and Justin Waring

Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation pp. 1257-1270

Eddie Gibson, Ian Koblbauer, Najida Begum, George Dranitsaris, Danny Liew, Phil McEwan, Amir Abbas Tahami Monfared, Yong Yuan, Ariadna Juarez-Garcia, David Tyas and Michael Lees

The Implementation of Managed Entry Agreements in Central and Eastern Europe: Findings and Implications pp. 1271-1285

Alessandra Ferrario, Diāna Arāja, Tomasz Bochenek, Tarik Čatić, Dávid Dankó, Maria Dimitrova, Jurij Fürst, Ieva Greičiūtė-Kuprijanov, Iris Hoxha, Arianit Jakupi, Erki Laidmäe, Olga Löblová, Ileana Mardare, Vanda Markovic-Pekovic, Dmitry Meshkov, Tanja Novakovic, Guenka Petrova, Maciej Pomorski, Dominik Tomek, Luka Voncina, Alan Haycox, Panos Kanavos, Patricia Vella Bonanno and Brian Godman

The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment pp. 1287-1296

Sabine Elisabeth Grimm, Mark Strong, Alan Brennan and Allan J. Wailoo

Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix®) to Guide Treatment of Patients with Depression and/or Anxiety pp. 1297-1310

Mehdi Najafzadeh, Jorge A. Garces and Alejandra Maciel

Volume 35, issue 11, 2017

Predictive Validation and the Re-Analysis of Cost-Effectiveness: Do We Dare to Tread? pp. 1111-1112

Jonathan Karnon and Hossein Hajiali Afzali

Replicating Health Economic Models: Firm Foundations or a House of Cards? pp. 1113-1121

Inigo Bermejo, Paul Tappenden and Ji-Hee Youn

A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection pp. 1123-1140

Hannah E. Burton, Stephen A. Mitchell and Maureen Watt

Certolizumab Pegol for Treating Rheumatoid Arthritis Following Inadequate Response to a TNF-α Inhibitor: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1141-1151

Iñigo Bermejo, Matt Stevenson, Rachel Archer, John W. Stevens, Edward Goka, Mark Clowes, David L. Scott and Adam Young

The Indonesian EQ-5D-5L Value Set pp. 1153-1165

Fredrick Dermawan Purba, Joke A. M. Hunfeld, Aulia Iskandarsyah, Titi Sahidah Fitriana, Sawitri Supardi Sadarjoen, Juan Manuel Ramos-Goñi, Jan Passchier and Jan J. V. Busschbach

Mapping PROMIS Global Health Items to EuroQol (EQ-5D) Utility Scores Using Linear and Equipercentile Equating pp. 1167-1176

Nicolas R. Thompson, Brittany R. Lapin and Irene L. Katzan

Examining the Feasibility and Utility of Estimating Partial Expected Value of Perfect Information (via a Nonparametric Approach) as Part of the Reimbursement Decision-Making Process in Ireland: Application to Drugs for Cancer pp. 1177-1185

Laura McCullagh, Susanne Schmitz, Michael Barry and Cathal Walsh

Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?” pp. 1187-1188

Emma McManus and Tracey Sach

Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’ pp. 1189-1190

Inigo Bermejo, Paul Tappenden and Ji-Hee Youn

Volume 35, issue 10, 2017

ICER’s Revised Value Assessment Framework for 2017–2019: A Critique pp. 977-980

Peter J. Neumann and Joshua T. Cohen

Availability and Pricing New Medicines in Ireland: Reflections and Reform pp. 981-987

Paul Gorecki

Discrete Event Simulation-Based Resource Modelling in Health Technology Assessment pp. 989-1006

Syed Salleh, Praveen Thokala, Alan Brennan, Ruby Hughes and Simon Dixon

Reporting and Analysis of Trial-Based Cost-Effectiveness Evaluations in Obstetrics and Gynaecology pp. 1007-1033

Mohamed El Alili, Johanna M. Dongen, Judith A. F. Huirne, Maurits W. Tulder and Judith E. Bosmans

Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 1035-1046

Nigel Fleeman, Adrian Bagust, Angela Boland, Sophie Beale, Marty Richardson, Ashma Krishan, Angela Stainthorpe, Ahmed Abdulla, Eleanor Kotas, Lindsay Banks and Miranda Payne

Assessing the Value of Biosimilars: A Review of the Role of Budget Impact Analysis pp. 1047-1062

Steven Simoens, Ira Jacobs, Robert Popovian, Leah Isakov and Lesley G. Shane

Performance-Based Risk-Sharing Arrangements: An Updated International Review pp. 1063-1072

Josh J. Carlson, Shuxian Chen and Louis P. Garrison

Prioritizing Future Research on Allopurinol and Febuxostat for the Management of Gout: Value of Information Analysis pp. 1073-1085

Eric Jutkowitz, Fernando Alarid-Escudero, Hyon K. Choi, Karen M. Kuntz and Hawre Jalal

Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008–2012 pp. 1087-1101

Abaigeal D. Jackson, Andrew L. Jackson, Godfrey Fletcher, Gerardine Doyle, Mary Harrington, Shijun Zhou, Fiona Cullinane, Charles Gallagher and Edward McKone

Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code pp. 1103-1109

Jörgen Möller, Sarah Davis, Matt Stevenson and J. Jaime Caro

Volume 35, issue 9, 2017

Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet? pp. 859-866

Caroline Vass and Katherine Payne

Informing Reimbursement Decisions Using Cost-Effectiveness Modelling: A Guide to the Process of Generating Elicited Priors to Capture Model Uncertainties pp. 867-877

Laura Bojke, Bogdan Grigore, Dina Jankovic, Jaime Peters, Marta Soares and Ken Stein

Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review pp. 879-893

Darío Rubio-Rodríguez, Silvia Diego Blanco, Maite Pérez and Carlos Rubio-Terrés

Health-Related Resource-Use Measurement Instruments for Intersectoral Costs and Benefits in the Education and Criminal Justice Sectors pp. 895-908

Susanne Mayer, Aggie T. G. Paulus, Agata Łaszewska, Judit Simon, Ruben M. W. A. Drost, Dirk Ruwaard and Silvia M. A. A. Evers

Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 909-919

Philip Morgan, Nerys Woolacott, Mousumi Biswas, Teumzghi Mebrahtu, Melissa Harden and Robert Hodgson

The Cost of Relapse in Schizophrenia pp. 921-936

Mark Pennington and Paul McCrone

Simulation Modelling in Healthcare: An Umbrella Review of Systematic Literature Reviews pp. 937-949

Syed Salleh, Praveen Thokala, Alan Brennan, Ruby Hughes and Andrew Booth

Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling pp. 951-962

Howard Thom, Chris Jackson, Nicky Welton and Linda Sharples

Erratum to: Using Parameter Constraints to Choose State Structures in Cost-Effectiveness Modelling pp. 963-963

Howard Thom, Chris Jackson, Nicky Welton and Linda Sharples

Distribution-Weighted Cost-Effectiveness Analysis Using Lifetime Health Loss pp. 965-974

Ulrikke J. V. Hernæs, Kjell A. Johansson, Trygve Ottersen and Ole F. Norheim

Ahead of Our Time: Collaboration in Modeling Then and Now pp. 975-976

Renée J. G. Arnold and Sean Ekins

Volume 35, issue 8, 2017

Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling pp. 755-757

Anthony J. Hatswell and Fleur Chandler

Evaluation of Healthcare Interventions and Big Data: Review of Associated Data Issues pp. 759-765

Carl V. Asche, Brian Seal, Kristijan H. Kahler, Elisabeth M. Oehrlein and Meredith Greer Baumgartner

How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis pp. 767-776

Laura Bojke, Andrea Manca, Miqdad Asaria, Ronan Mahon, Shijie Ren and Stephen Palmer

Defining and Measuring the Affordability of New Medicines: A Systematic Review pp. 777-791

Fernando Antoñanzas, Robert Terkola, Paul M. Overton, Natalie Shalet and Maarten Postma

Does the Public Prefer Health Gain for Cancer Patients? A Systematic Review of Public Views on Cancer and its Characteristics pp. 793-804

Liz Morrell, Sarah Wordsworth, Sian Rees and Richard Barker

Adalimumab for Treating Moderate-to-Severe Hidradenitis Suppurativa: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 805-815

Paul Tappenden, Christopher Carroll, John W. Stevens, Andrew Rawdin, Sabine Grimm, Mark Clowes, Eva Kaltenthaler, John R. Ingram, Fiona Collier and Mohammad Ghazavi

A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models pp. 817-830

Chase Hollman, Mike Paulden, Petros Pechlivanoglou and Christopher McCabe

Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States pp. 831-844

Min Huang, Yanyan Lou, James Pellissier, Thomas Burke, Frank Xiaoqing Liu, Ruifeng Xu and Vamsidhar Velcheti

Using Genomic Information to Guide Ibrutinib Treatment Decisions in Chronic Lymphocytic Leukaemia: A Cost-Effectiveness Analysis pp. 845-858

James Buchanan, Sarah Wordsworth, Ruth Clifford, Pauline Robbe, Jenny C. Taylor, Anna Schuh and Samantha J. L. Knight

Volume 35, issue 7, 2017

Defining Value: The Need for a Longer, Broader View pp. 669-672

Tomas Philipson, Sachin Kamal-Bahl and Anupam B. Jena

Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview pp. 673-683

Erik J. Dasbach and Elamin H. Elbasha

Regression-Based Approaches to Patient-Centered Cost-Effectiveness Analysis pp. 685-695

Daisuke Goto, Ya-Chen Shih, Pascal Lecomte, Melvin Olson, Chukwukadibia Udeze, Yujin Park and C. Daniel Mullins

Discrete Choice Experiments: A Guide to Model Specification, Estimation and Software pp. 697-716

Emily Lancsar, Denzil Fiebig and Arne Hole

Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 717-726

Lesley Uttley, Sophie Whyte, Timothy Gomersall, Shijie Ren, Ruth Wong, Duncan Chambers and Paul Tappenden

Emerging Use of Early Health Technology Assessment in Medical Product Development: A Scoping Review of the Literature pp. 727-740

Maarten J. IJzerman, Hendrik Koffijberg, Elisabeth Fenwick and Murray Krahn

An Investigation of the Overlap Between the ICECAP-A and Five Preference-Based Health-Related Quality of Life Instruments pp. 741-753

Lidia Engel, Duncan Mortimer, Stirling Bryan, Scott A. Lear and David G. T. Whitehurst

Volume 35, issue 6, 2017

How Qualitative Methods Can be Used to Inform Model Development pp. 607-612

Samantha Husbands, Susan Jowett, Pelham Barton and Joanna Coast

Bayesian Methods for Calibrating Health Policy Models: A Tutorial pp. 613-624

Nicolas A. Menzies, Djøra I. Soeteman, Ankur Pandya and Jane J. Kim

Are Quality-Adjusted Life Years a Good Proxy Measure of Individual Capabilities? pp. 637-646

Paul Mark Mitchell, Sridhar Venkatapuram, Jeff Richardson, Angelo Iezzi and Joanna Coast

An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis pp. 647-659

Paul Tappenden, Susannah Sadler and Martin Wildman

Comment on: “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal” pp. 661-663

Odette Reifsnider, Fiona Hall, Sonja Sorensen, Irina Proskorovsky, Isabelle Girod and Jennifer Lee

Response to Letter to the Editor Regarding “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal” pp. 665-667

Bram L. T. Ramaekers, Rob Riemsma, Florian Tomini, Thea Asselt, Sohan Deshpande, Steven Duffy, Nigel Armstrong, Johan L. Severens, Jos Kleijnen and Manuela A. Joore

Volume 35, issue 5, 2017

Pharmacy Benefit Management Companies: Do They Create Value in the US Healthcare System? pp. 493-500

Alan Lyles

Methodological Issues Surrounding the Use of Baseline Health-Related Quality of Life Data to Inform Trial-Based Economic Evaluations of Interventions Within Emergency and Critical Care Settings: A Systematic Literature Review pp. 501-515

Melina Dritsaki, Felix Achana, James Mason and Stavros Petrou

Economic Evaluations of New Oral Anticoagulants for the Prevention of Venous Thromboembolism After Total Hip or Knee Replacement: A Systematic Review pp. 517-535

James Brockbank and Sorrel Wolowacz

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 537-547

Christopher Carroll, Paul Tappenden, Rachid Rafia, Jean Hamilton, Duncan Chambers, Mark Clowes, Paul Durrington, Nadeem Qureshi and Anthony S. Wierzbicki

Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland–Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data pp. 549-559

Jason Madan, Kamran A. Khan, Stavros Petrou and Sarah E. Lamb

Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study pp. 561-573

Matthew Franklin, Sarah Davis, Michelle Horspool, Wei Sun Kua and Steven Julious

The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling pp. 575-589

Asrul Shafie, Hui Yee Yeo, Laurent Coudeville, Lucas Steinberg, Balvinder Singh Gill, Rohani Jahis and Amar-Singh Hss

Making Implicit Assumptions Explicit in the Costing of Informal Care: The Case of Head and Neck Cancer in Ireland pp. 591-601

Paul Hanly, Rebecca Maguire, Myles Balfe, Eleanor O’Sullivan and Linda Sharp

Comment on: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation” pp. 603-604

Afschin Gandjour

Authors’ Reply to Gandjour: “Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation” pp. 605-606

Monika Wagner and Mireille Goetghebeur

Volume 35, issue 4, 2017

Economic Studies in Motor Neurone Disease: A Systematic Methodological Review pp. 397-413

Alan Moore, Carolyn A. Young and Dyfrig A. Hughes

Cabazitaxel for Hormone-Relapsed Metastatic Prostate Cancer Previously Treated With a Docetaxel-Containing Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 415-424

Benjamin Kearns, Abdullah Pandor, Matt Stevenson, Jean Hamilton, Duncan Chambers, Mark Clowes, John Graham and M. Satish Kumar

Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma pp. 425-438

Kelly Fust, Xiaoyan Li, Michael Maschio, Guillermo Villa, Anju Parthan, Richard Barron, Milton C. Weinstein, Luc Somers, Caroline Hoefkens and Gary H. Lyman

Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration? pp. 439-451

Brendan Mulhern, Richard Norman, Paula Lorgelly, Emily Lancsar, Julie Ratcliffe, John Brazier and Rosalie Viney

Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15 pp. 453-467

Christine Mpundu-Kaambwa, Gang Chen, Remo Russo, Katherine Stevens, Karin Dam Petersen and Julie Ratcliffe

Measuring Care-Related Quality of Life of Caregivers for Use in Economic Evaluations: CarerQol Tariffs for Australia, Germany, Sweden, UK, and US pp. 469-478

Renske J. Hoefman, Job van Exel and Werner Brouwer

A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK pp. 479-491

C. Rinciog, M. Watkins, S. Chang, T. M. Maher, C. LeReun, D. Esser and A. Diamantopoulos

Volume 35, issue 3, 2017

Weighing Clinical Evidence Using Patient Preferences: An Application of Probabilistic Multi-Criteria Decision Analysis pp. 259-269

Henk Broekhuizen, Maarten J. IJzerman, A. Brett Hauber and Catharina G. M. Groothuis-Oudshoorn

A Systematic Review and Critical Appraisal of Economic Evaluations of Pharmacological Interventions for People with Bipolar Disorder pp. 271-296

Ifigeneia Mavranezouli and Joran Lokkerbol

A Systematic Review of Cardiovascular Outcomes-Based Cost-Effectiveness Analyses of Lipid-Lowering Therapies pp. 297-318

Ching-Yun Wei, Ruben G. W. Quek, Guillermo Villa, Shravanthi R. Gandra, Carol A. Forbes, Steve Ryder, Nigel Armstrong, Sohan Deshpande, Steven Duffy, Jos Kleijnen and Peter Lindgren

How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review pp. 319-329

Xinyang Hua, Thomas Wai-Chun Lung, Andrew Palmer, Lei Si, William H. Herman and Philip Clarke

The Valuation of Informal Care in Cost-of-Illness Studies: A Systematic Review pp. 331-345

Juan Oliva, Marta Trapero-Bertran, Luz Maria Peña-Longobardo and Raúl del Pozo-Rubio

Valuing Meta-Health Effects for Use in Economic Evaluations to Inform Reimbursement Decisions: A Review of the Evidence pp. 347-362

Richard Abreu Lourenco, Marion Haas, Jane Hall and Rosalie Viney

Azacitidine for Treating Acute Myeloid Leukaemia with More Than 30 % Bone Marrow Blasts: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal pp. 363-373

Irina A. Tikhonova, Martin W. Hoyle, Tristan M. Snowsill, Chris Cooper, Joanna L. Varley-Campbell, Claudius E. Rudin and Ruben E. Mujica Mota

Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM) pp. 375-396

Michael Willis, Pierre Johansen, Andreas Nilsson and Christian Asseburg

Volume 35, issue 2, 2017

Emergent Challenges in Determining Costs for Economic Evaluations pp. 129-139

Josephine C. Jacobs and Paul G. Barnett

Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus pp. 141-162

Asrul Shafie, Chin Hui Ng, Yui Ping Tan and Nathorn Chaiyakunapruk

Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy pp. 163-176

Anthony J. Hatswell, Nick Freemantle and Gianluca Baio

Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update pp. 177-190

Spencer M. Vale, Dane Hill and Steven R. Feldman

Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal pp. 191-202

Bram L. T. Ramaekers, Rob Riemsma, Florian Tomini, Thea Asselt, Sohan Deshpande, Steven Duffy, Nigel Armstrong, Johan L. Severens, Jos Kleijnen and Manuela A. Joore

A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence pp. 203-213

Ros Wade, Robert Hodgson, Mousumi Biswas, Melissa Harden and Nerys Woolacott

A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010–2016 pp. 215-223

Jacquelyn McRae, F. Randy Vogenberg, Silky Webb Beaty, Elizabeth Mearns, Stefan Varga and Laura Pizzi

Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK pp. 225-235

Richard Lawson, James Ryan, Frederic King, Jo Wern Goh, Eszter Tichy and Kevin Marsh

Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom pp. 237-248

Lindsay Claxton, Robert Hodgson, Matthew Taylor, Bill Malcolm and Ruth Pulikottil Jacob

Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis pp. 249-258

Erik Landfeldt, Lars Alfredsson, Volker Straub, Hanns Lochmüller, Katharine Bushby and Peter Lindgren

Volume 35, issue 1, 2017

Measuring the Value of Pharmaceuticals in the US Health System pp. 1-4

Surrey M. Walton, Anirban Basu, John Mullahy, Samuel Hong and Glen T. Schumock

Heath State Utility Values for Cost-Effectiveness Models pp. 1-3

Jonathan Karnon

Discounting the Recommendations of the Second Panel on Cost-Effectiveness in Health and Medicine pp. 5-13

Mike Paulden, James F. O’Mahony and Christopher McCabe

Special Edition on Utility Measurement, PharmacoEconomics pp. 5-6

Andrew Lloyd

Sourcing and Using Appropriate Health State Utility Values in Economic Models in Health Care pp. 7-9

Roberta Ara, Tessa Peasgood, Clara Mukuria, Helene Chevrou-Severac, Donna Rowen, Ismail Azzabi-Zouraq, Suzy Paisley, Tracey Young, Ben Hout and John Brazier

International Regulations and Recommendations for Utility Data for Health Technology Assessment pp. 11-19

Donna Rowen, Ismail Azzabi Zouraq, Helene Chevrou-Severac and Ben Hout

Modeling Treatment Sequences in Pharmacoeconomic Models pp. 15-24

Ying Zheng, Feng Pan and Sonja Sorensen

A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models pp. 21-31

John Brazier, Roberta Ara, Donna Rowen and Helene Chevrou-Severac

The Societal Cost of Schizophrenia: A Systematic Review pp. 25-42

Huajie Jin and Iris Mosweu

The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment pp. 33-41

Donna Rowen, John Brazier, Roberta Ara and Ismail Azzabi Zouraq

The Identification, Review and Synthesis of Health State Utility Values from the Literature pp. 43-55

Roberta Ara, John Brazier, Tessa Peasgood and Suzy Paisley

Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations pp. 43-63

Simon van der Schans, Lucas M. A. Goossens, Melinde R. S. Boland, Janwillem W. H. Kocks, Maarten J. Postma, Job F. M. van Boven and Maureen P. M. H. Rutten- van Mölken

The Use of Mapping to Estimate Health State Utility Values pp. 57-66

Roberta Ara, Donna Rowen and Clara Mukuria

Challenges in Cost-Effectiveness Analysis Modelling of HPV Vaccines in Low- and Middle-Income Countries: A Systematic Review and Practice Recommendations pp. 65-82

Obinna I. Ekwunife, James F. O’Mahony, Andreas Gerber Grote, Christoph Mosch, Tatjana Paeck and Stefan K. Lhachimi

Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies pp. 67-75

Roberta Ara, John Brazier and Tracey Young

The Use of Health State Utility Values in Decision Models pp. 77-88

Roberta Ara, John Brazier and Ismail Azzabi Zouraq

Economic Evaluations of First-Line Chemotherapy Regimens for Pancreatic Cancer: A Critical Review pp. 83-95

Mahdi Gharaibeh, J. Lyle Bootman, Ali McBride, Jennifer Martin and Ivo Abraham

Estimating Health State Utility Values for Comorbidities pp. 89-94

Roberta Ara and John Brazier

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal pp. 97-109

Paul Tappenden, Sue Harnan, Shijie Ren, Praveen Thokala, Ruth Wong, Clara Mukuria, Clare Green, Simon Pledge and John Tidy

Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs) pp. 111-124

Billingsley Kaambwa, Gang Chen, Julie Ratcliffe, Angelo Iezzi, Aimee Maxwell and Jeff Richardson

Benefits, Challenges and Potential Strategies of Open Source Health Economic Models pp. 125-128

William C. N. Dunlop, Nicola Mason, James Kenworthy and Ron L. Akehurst